NPS Intelligence (beta)

Disclosed NPS & retention by vertical

Verticals  /  Pharma, medtech & health distribution  /  Owens & Minor, Inc.

Owens & Minor, Inc.

Pharma, medtech & health distributionHealthcare DistributorACH
—
Latest disclosed NPS
no score published
6
NPS entries
0 with a number
2020–26
Years covered
7 entries in all

In their words

“This continues to be validated by Net Promoter Scores that have exceeded the industry average for the last several years. We also have a broad range of growing product offerings and capabilities, which provides us the ability to serve patients in the…”
— Edward Pesicka, Chief Executive Officer, Owens & Minor, Inc. · Earnings call, Q4 2025 · 19 Feb 2026
“Net Promoter Scores of 2-3x Commercial (3) healthcare benchmarks p. 12 p.”
— Owens & Minor, Inc. · SEC 8-K filing · filed 11 May 2026
“Leader in Home-based Care Access to ~85% of U.S. population Growing Medicare Advantage population Majority of payor partnerships are evergreen Rated Best Overall Diabetes Supplier 2020-2023 Net Promoter Scores of 2-3x healthcare benchmarks 1 As of FY24.”
— Owens & Minor, Inc. · SEC 8-K filing · filed 20 Mar 2025

NPS disclosures (6)

Search the database →

11 May 2026
NPSProgram

…Net Promoter Scores of 2-3x Commercial (3) healthcare benchmarks p. 12 p.

— Owens & Minor, Inc. · SEC 8-K filing · filed 11 May 2026
SEC 8-K filing ↗
19 Feb 2026
NPSProgram

This continues to be validated by Net Promoter Scores that have exceeded the industry average for the last several years. We also have a broad range of growing product offerings and capabilities, which provides us the ability to serve patients in the…

— Edward Pesicka, Chief Executive Officer, Owens & Minor, Inc. · Earnings call, Q4 2025 · 19 Feb 2026
Earnings call, Q4 2025 ↗
20 Mar 2025
NPSProgram

…Leader in Home-based Care Access to ~85% of U.S. population Growing Medicare Advantage population Majority of payor partnerships are evergreen Rated Best Overall Diabetes Supplier 2020-2023 Net Promoter Scores of 2-3x healthcare benchmarks 1 As of FY24.

— Owens & Minor, Inc. · SEC 8-K filing · filed 20 Mar 2025
SEC 8-K filing ↗
3 Feb 2025
NPSProgram

…Access to ~85% of U.S. population Growing Medicare Advantage population Majority of payor partnerships are evergreen Rated Best Overall Diabetes Supplier 2020-2023 Net Promoter Scores of 2-3x healthcare benchmarks 290M Active patients ~3M 1 As of FY23.

— Owens & Minor, Inc. · SEC 8-K filing · filed 3 Feb 2025
SEC 8-K filing ↗
6 Dec 2023
NPSProgram

…Net Promoter Scores of 2-3x healthcare benchmarks Proprietary to Owens & Minor, Inc. 40 Market Leader in Home-based Care 1200+ Branded manufacturers Contracted with High Quality Manufacturers Proprietary to Owens & Minor, Inc.

— Owens & Minor, Inc. · SEC 8-K filing · filed 6 Dec 2023
SEC 8-K filing ↗
26 May 2021
NPSProgram

…Managed Care Contracts…650+ with over 2,000 plan designs Nationwide Network to Optimize Shipping Distance and Time Consistently High Patient Satisfaction Scores: NPS > 2x Healthcare Industry Benchmarks Providing Quality Products Across Markets…

— Owens & Minor, Inc. · SEC 8-K filing · filed 26 May 2021
SEC 8-K filing ↗

Retention disclosures (1)

Open in the retention database →

9 Oct 2020
Retention

Fitch ratings note Owens & Minor's focus on customer wins and retention as a driver of revenue growth.

— reported by fitchratings.com · 9 Oct 2020
fitchratings.com ↗

Lighthouse companies in Pharma, medtech & health distribution

The whole vertical →

About these figures

Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.

NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.